NCT02547922已完成2 期
A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects With Active Proliferative Lupus Nephritis
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 147
- 试验地点
- 1
- 主要终点
- Change From Baseline in 24-hour Urine Protein to Creatinine Ratio (UPCR)
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of two doses of anifrolumab versus placebo in adult subjects with active proliferative lupus nephritis (LN).
详细描述
This is a Phase 2, multicentre, multinational, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of two intravenous (IV) treatment regimens of anifrolumab versus placebo while taking standard of care (SOC) treatment with mycophenolate mofetil (MMF) and corticosteroids in adult subjects with active proliferative lupus nephritis (LN).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 through 70 years at the time of screening
- •Fulfils at least 4 of the 11 criteria of the revised 1982 ACR classification criteria for SLE, at least one of which must be:
- •Positive antinuclear antibody (ANA) test (1:40 or higher) or
- •Elevated anti-dsDNA antibodies at screening (reported as equivocal or positive results), as per the centrallaboratory; or
- •Anti-Smith antibody at screening elevated to above normal (ie, positive or equivocal results) as per the central laboratory
- •Class III (±Class V) or Class IV (±Class V) LN according to the World Health Organisation (WHO) or 2003 ISN/RPS classification based on a renal biopsy obtained within 12 weeks prior to signing the ICF or during the screening period:
- •Urine protein to creatinine ratio >1 gm/gm (113.17 mg/mmol), obtained on a 24-hour urine collection at screening
- •Estimated glomerular filtration rate ≥35 mL/min/1.73 m2
- •Must not have active or latent TB on either chest radiograph or by Quantiferon gold test
- •Women of childbearing potential must have a negative serum beta-hCG test at screening and negative urine pregnancy test prior to the first dose of sponsor-provided MMF.
排除标准
- •Receipt of any investigational product (small molecule or biologic) or commercially available biologic agent within four weeks or 5 half lives prior to signing of the ICF, whichever is greater
- •Pure Class V membranous LN on a renal biopsy obtained within 12 weeks prior to signing ICF or during the screening period
- •Known intolerance to ≤1.0 gm/day of MMF
- •History of dialysis within 12 months prior to signing the ICF or expected need for renal replacement therapy (dialysis or renal transplant) within a 6 month period after enrolment
- •Subjects, who at the time of signing the ICF, received any of the following immunosuppressive therapies after their qualifying biopsy
- •Oral corticosteroids >0.5 mg/kg/day for more than 8 weeks or
- •Oral or IV pulse methylprednisolone >3.0 gm (cumulative dose) or
- •IV cyclophosphamide >2 pulses of high-dose (≥0.5 gm/m2) or >4 doses of low dose (500 mg every 2 weeks) or
- •Average MMF >2.5 gm/day (>1800 mg/day of enteric-coated mycophenolate sodium) for more than 8 weeks or
- •Tacrolimus >4 mg/day for more than 8 weeks
- •Major surgery within 8 weeks before signing the ICF or major surgery planned during the study period
- •History of any non-SLE disease that has required treatment with oral or parenteral corticosteroids for more than a total of 2 weeks within the last 24 weeks prior to signing the ICF
- •Confirmed positive test for hepatitis B or hepatitis C
- •Any severe herpes infection at any time prior to randomization
- •Opportunistic infection requiring hospitalisation or parenteral antimicrobial treatment within 3 years prior to randomization (vaginal, oral and skin candidiasis is not an exclusionreason).
- •History of cancer, apart from:
- •Squamous or basal cell carcinoma of the skin that has been successfully treated
- •Cervical cancer in situ that has been successfully treated
- •Concurrent enrolment in another clinical study with an IP within 4 weeks prior to ICF signing or within 5 half-lives of the IP used in that clinical study, whichever is longer.
- •During screening (within 30 days before Day 1 [Week 0 visit]), any of the following:
- •Aspartate transaminase (AST) >2.5×upper limit of normal (ULN)
- •Alanine transaminase (ALT) >2.5×ULN
- •Total bilirubin >ULN (unless due to Gilbert's syndrome [based on Investigator's judgement])
- •Glycosylated haemoglobin (HbA1c) >8% (or >0.08) at screening (diabetic subjects only)
- •Neutrophil count <1x103/μL (or <1.0 GI/L)
- •Platelet count <25x103/μL (or <25 GI/L)
- •Haemoglobin <8 g/dL (or <80 g/L).
研究组 & 干预措施
Anifrolumab - Lower Dose
Experimental
Anifrolumab - Lower Dose
干预措施: Anifrolumab (Biological)
Anifrolumab - Higher Dose
Experimental
Anifrolumab - Higher Dose
干预措施: Anifrolumab (Biological)
Placebo
Placebo Comparator
Placebo IV Q4W plus SOC
干预措施: Placebo (Drug)
结局指标
主要结局
Change From Baseline in 24-hour Urine Protein to Creatinine Ratio (UPCR)
时间窗: From Week 1 (Baseline) up to Week 52
To evaluate the efficacy of anifrolumab plus SOC (combination of mycophenolate mofetil and corticosteroids) compared with placebo plus SOC in subjects with active proliferative lupus nephritis (LN). Geometric mean ratio of 24-hour UPCR at week 52 over baseline. Values \<1 indicate improvement from baseline.
次要结局
- Proportion of Subjects Achieving the Composite Endpoint Complete Renal Response (CRR)(Week 52)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Anifrolumab Asian PhIII Efficacy Study for Systemic Lupus Erythematosus (SLE)Active Systemic Lupus ErythematosusNCT04931563AstraZeneca277
已完成
3 期
Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus ErythematosusActive Systemic Lupus ErythematosusNCT02446912AstraZeneca460
已完成
3 期
Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus ErythematosusActive Systemic Lupus ErythematosusNCT02446899AstraZeneca373
已完成
3 期
Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHFAcute Heart FailureNCT01870778Novartis Pharmaceuticals6,600
终止
3 期
Efficacy, Safety and Tolerability of Sexelaxin When Added to Standard Therapy in AHFAcute Heart FailureNCT02007720Novartis Pharmaceuticals876